Lopez-Beltran A, Luque R J, Moreno A, Bollito E, Carmona E, Montironi R
Department of Pathology, Cordoba University Medical School and Reina Sofia University Hospital, Cordoba, Spain.
Virchows Arch. 2002 Aug;441(2):148-53. doi: 10.1007/s00428-002-0627-8. Epub 2002 Apr 4.
Pagetoid urothelial carcinoma in situ (CIS) is a rare variant of bladder cancer that is characterized by an intraepithelial proliferation of large cells arranged singly or in clusters and randomly distributed. These neoplasms deserve recognition and attention, chiefly because they may be overlooked or misdiagnosed as urothelial dysplasia, then causing unsuspected tumor recurrence after surgery. We report on the clinicopathological features and immunohistochemical findings of 11 (14.86%) cases of pagetoid CIS in a retrospective study of 74 cases of conventional carcinoma in situ. Most patients were male ( n=10). Their ages ranged from 31 years to 78 years. The lesion can be present with primary ( n=2) or secondary ( n=9) CIS. Pagetoid CIS is usually a focal lesion occurring in a clinical and histological setting of conventional CIS, and these patients essentially have the same progression and survival rates as patients without pagetoid changes and are treated in the same way. In cases with extensive urothelial denudation, pagetoid CIS may be focally present in otherwise normal-looking urothelium, thus alerting the pathologist to search for additional CIS elsewhere in the bladder. Given that primary extramammary Paget disease of the external genitalia and of the anal canal may extend to the bladder and, conversely, some bladder cases of pagetoid CIS may extend to the urethra, ureter, and beyond to the external genitalia, the differential diagnoses between these two entities represent an important therapeutic consideration. Our data suggest that a panel of immunostains including CK7+/CK20+/TM+ may assist in differentiating urothelial pagetoid CIS from extramammary Paget disease which is known to be CK7+/CK20-.
派杰样原位尿路上皮癌(CIS)是膀胱癌的一种罕见变体,其特征是大细胞在上皮内呈单个或成簇增殖,并随机分布。这些肿瘤值得识别和关注,主要是因为它们可能被忽视或误诊为尿路上皮发育异常,进而导致术后意外的肿瘤复发。在一项对74例传统原位癌的回顾性研究中,我们报告了11例(14.86%)派杰样CIS的临床病理特征和免疫组化结果。大多数患者为男性(n = 10)。他们的年龄在31岁至78岁之间。病变可表现为原发性(n = 2)或继发性(n = 9)CIS。派杰样CIS通常是在传统CIS的临床和组织学背景下出现的局灶性病变,这些患者的进展和生存率与无派杰样改变的患者基本相同,治疗方式也相同。在尿路上皮广泛剥脱的病例中,派杰样CIS可能局灶性存在于外观正常的尿路上皮中,从而提醒病理学家在膀胱其他部位寻找额外的CIS。鉴于外生殖器和肛管的原发性乳腺外派杰病可能蔓延至膀胱,反之,一些膀胱派杰样CIS病例可能蔓延至尿道、输尿管,并延伸至外生殖器,这两种实体之间的鉴别诊断是一个重要的治疗考虑因素。我们的数据表明,一组免疫染色,包括CK7+/CK20+/TM+,可能有助于将尿路上皮派杰样CIS与已知为CK7+/CK20-的乳腺外派杰病区分开来。